CEMP Cempra, Inc.

2.83
-0.18  -5.84%
Previous Close 3.00
Open 3.05
Price To book 0.76
Market Cap 147.98M
Shares 52,381,000
Volume 2,615,858
Short Ratio 2.14
Av. Daily Volume 3,134,980

SEC filingsSee all SEC filings

  1. 8-K - Current report 17515800
  2. 8-K - Current report 162073505
  3. 8-K - Current report 162045443
  4. 8-K - Current report 162032733
  5. 8-K - Current report 161997870

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL announced December 29, 2016. Further trials required.
Solithera - intravenous
Community-acquired bacterial pneumonia (CABP)
CRL announced December 29, 2016. Further trials required.
Solithera - oral
Community-acquired bacterial pneumonia (CABP)
Phase 2 interim data released September 30, 2016. Enrollment completed. Data to be presented at upcoming conference. No timeline given.
Solithromycin
NASH
Phase 3 initiated August 2014. Enrollment completed December 2015 but decided to increase enrollment. Noted January 9, 2017 that extension enrollment has been slower than envisaged.
Solithromycin
Uncomplicated urogenital gonococcal infections
Phase 3 data due 1Q 2017.
Taksta - Fusidic acid
Acute bacterial skin and skin structure infections (ABSSSI)
Phase 2 trial discontinued - noted January 9, 2017.
Solithromycin
COPD

Latest News

  1. Cempra (CEMP): An Off-the-Radar Potential Winner
  2. Latest Reports on Sarepta Therapeutics and Cempra as the NASDAQ Continues to Hit Record Highs
  3. CEMPRA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  4. Cempra to Present at J.P. Morgan Healthcare Conference
  5. INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Cempra, Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm
  6. INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Cempra, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 3, 2017
  7. Is the Options Market Predicting a Spike in Cempra (CEMP) Stock?
  8. Cempra (CEMP) Worth a Look: Stock Jumps 7.7% in Session
  9. EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Cempra, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
  10. Cempra: You Can Brag…
  11. GPM Reminds Investors of the January 3 Deadline in the Class Action Lawsuit Against Cempra, Inc.
  12. Cempra (CEMP) Gets CRL from FDA for Pneumonia Candidate
  13. Top Analyst Upgrades and Downgrades: Tesla Motors, Kate Spade, Xilinx, Yandex, Cempra and More
  14. Blog Coverage Cempra's Stock Price Dropped Following US FDA Rejection of Its Pneumonia Drug
  15. Cempra shares crater on concerns about delay in getting pneumonia drug approved
  16. Cempra upgraded by Morgan Stanley
  17. Pharma Stock Roundup: Cempra Plunges to 52-Week Low, Shire Drug Label Expanded
  18. For Cempra, feasibility of FDA-suggested study yet to be determined
  19. Cempra, xG Technology Slide into Thursday’s 52-Week Low Club
  20. Nvidia (NVDA) Can’t Shake Citron, Cempra (CEMP) Slammed by FDA Rejection, Plus 3 Other Major Movers

SEC Filings

  1. 8-K - Current report 17515800
  2. 8-K - Current report 162073505
  3. 8-K - Current report 162045443
  4. 8-K - Current report 162032733
  5. 8-K - Current report 161997870
  6. 8-K - Current report 161988228
  7. 8-K - Current report 161976436
  8. 8-K - Current report 161963425
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 161955899
  10. 8-K - Current report 161955893